Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883019 | 0.87 | PTPN1 (0.35) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL3432515 | 0.85 | HSD17B10 (0.37) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL26695036 | 0.78 | PTPN1 (0.35) | PTPN1NR1H2NR1H3CCR2EPHX2 | |
| SCHEMBL5495474 | 0.77 | PTPN1 (0.34) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL5379806 | 0.77 | PTPN1 (0.34) | PTPN1NR1H2NR1H3EPHX2CHRM2 | |
| SCHEMBL8337375 | 0.77 | NR1H2 (0.36) | PTPN1NR1H2NR1H3CCR2EPHX2 | |
| SCHEMBL883020 | 0.75 | HSD17B10 (0.38) | NR1H2EPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL5757068 | 0.73 | PTPN1 (0.38) | PTPN1NR1H2NR1H3CCR2CHRM2 | |
| SCHEMBL882907 | 0.72 | CHRM2 (0.36) | PTPN1NR1H2NR1H3CCR2EPHX2 | |
| SCHEMBL16914271 | 0.72 | NR1H2 (0.35) | PTPN1NR1H2NR1H3CCR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | PTPN1 3585/4885NR1H2 2556/4885NR1H3 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.